Dynamic International Prognostic Scoring System for Myelofibrosis
The Dynamic International Prognostic Scoring System predicts survival in myelofibrosis based on age, hemoglobin, leukocytosis, circulating blasts, and constitutional symptoms 1 [Level I evidence].
Indicazioni d'uso
Used for primary or secondary myelofibrosis at any time during the disease course to dynamically stratify survival risk based on age, hemoglobin, leukocytes, blasts, and constitutional symptoms 1 [Level I evidence]. Guides transplant referral, intensity of therapy, and timing of JAK inhibitor or clinical‑trial consideration; higher scores predict inferior post‑transplant survival 2 [Level II evidence].
Approfondimenti e precauzioni
Identifies survival risk using age >65, anemia, leukocytosis, blasts ≥1%, and constitutional symptoms, which dynamically worsen prognosis as factors are acquired 1 [Level I evidence]. High‑risk status strongly predicts inferior survival and post‑transplant mortality 2 [Level II evidence]. Use cautiously: lacks cytogenetics and molecular data, underestimates risk in adverse karyotype or high‑molecular‑risk mutations (e.g., ASXL1, SRSF2) incorporated later in DIPSS‑Plus 3 [Level I evidence].